The injections include one lot of Metoclopramide Injection — USP, 10 mg/2 mL — and two lots of Ondansetron Injection—USP, 4 mg/2 ML. The lots were distributed June through September of this year.
Hospira has not received any reports of adverse events associated with the recalled lots, but noted the potential for glass particles to dislodge into the solution, according to the report.
More Articles on Patient Safety:
The Power of the Checklist: How to Crete a Culture of Patient Safety at ASCs
Empowering Patients to Be Their Own Advocates in Healthcare Safety
10 Most Common General and Specific Adverse Drug Event Causes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
